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Summary
Hereditary nonpolyposis colorectal cancer (HNPCC)
(Amsterdam criteria) is often caused by mutations in
mismatch repair (MMR) genes, and tumors of patients
with HNPCC show microsatellite instability (MSI-high
phenotype). Germline mutations of MMR genes have
rarely been found in families that have HNPCC or sus-
pected HNPCC and that do not show microsatellite in-
stability (MSI-low phenotype). Therefore, an MSI-high
phenotype is often used as an inclusion criterion for
mutation testing ofMMR genes. Correction of base-base
mismatches is the major function of MSH6. Since mis-
matches present with an MSI-low phenotype, we as-
sumed that the phenotype in patients with HNPCC-re-
lated tumors might be associated with MSH6 germline
mutations. We divided 36 patients with suspected
HNPCC into an MSI-low group ( ) and an MSI-n = 18
high group ( ), on the basis of the results of MSIn = 18
testing. Additionally, three unrelated patients from Am-
sterdam families with MSI-low tumors were investi-
gated. All patients were screened forMSH2, MLH1, and
MSH6 mutations. Four presumably causative MSH6
mutations were detected in the patients (22%) who had
suspected HNPCC and MSI-low tumors. Furthermore,
we detected one frameshift mutation in one of the three
patients with HNPCC and MSI-low tumors. In theMSI-
high group, one MSH6 missense mutation was found,
but the same patient also had anMLH1mutation, which
may explain the MSI-high phenotype. These results sug-
gest that MSH6 may be involved in a substantial pro-
portion of patients with HNPCC or suspected HNPCC
and MSI-low tumors. Our data emphasize that an MSI-
low phenotype cannot be considered an exclusion cri-
terion for mutation testing of MMR genes in general.
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Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC
[MIM 120435 andMIM 120436]) is an autosomal dom-
inant disorder in which, in addition to colon cancer,
tumors also occur in the endometrium, small bowel, pan-
creas, biliary tract, stomach, ovary, and urinary tract.
Diagnosis of HNPCC is defined by the so-called Am-
sterdam criteria (Vasen et al. 1991): occurrence of his-
tologically verified colorectal cancer (CRC) in at least
three relatives (one of whom is a first-degree relative of
the other two) in at least two successive generations and
an age of !50 years at onset of CRC in one of the rel-
atives. Furthermore, familial adenomatous polyposis
should be excluded. Among all patients with CRC, how-
ever, only 1%–2% meet these strict criteria (Aaltonen
et al. 1998). A substantial proportion of the tumors in
the patients not meeting these strict criteria and in whom
familial polyposis is excluded might be called “suspected
HNPCC,” since several, but not all, of the criteria are
met.
Almost all tumors of patients with HNPCC demon-
strate microsatellite instability (MSI). MSI is the result
of such somatic frameshift mutations as small deletions
or insertions. These mutations are caused by a defective
DNA repair system (Aaltonen et al. 1993; Peltoma¨ki et
al. 1993). To date, germline mutations of five MMR
genes (MSH2, MLH1, PMS1, PMS2, and MSH6 [also
designated “GTBP”]) have been identified in patients
with HNPCC (Akiyama et al. 1997; Miyaki et al. 1997;
Peltoma¨ki et al. 1997). It has been shown that the large
majority of germline mutations found in families with
HNPCC that fulfill the Amsterdam criteria are detected
in MSH2 or MLH1 (Liu et al. 1996; Nystro¨m-Lahti et
al. 1996), both of which encode MMR enzymes that are
mainly involved in the repair of small insertions/de-
letions.
Germline mutations of MMR genes have rarely been
found in families that do not meet these criteria and that
display MSI-low tumors. This might point to involve-
ment of a tumor-suppressor gene in such families. In-
deed, a germline mutation of the TGFbRII gene, which
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encodes transforming growth factor–b, was recently de-
tected in a family with suspected HNPCC and an MSI-
low tumor phenotype (Lu et al. 1998). The importance
of transforming growth factor–b in tumorigenesis is al-
ready known, since somatic frameshift mutations at an
(A)10 repeat in the gene are frequently found in HNPCC-
associated tumors with an MSI-high phenotype (Mar-
kowitz et al. 1995). Nevertheless, the genes that are re-
sponsible for a majority of cases of HNPCC and
suspected HNPCC in families with MSI-low tumors are
unknown.
As an alternative to tumor-suppressor-gene involve-
ment, MMR genes such as MSH6 (Drummond et al.
1995), which encode enzymes involved in the repair of
base-base mismatches, cannot be excluded from play-
ing a role in these families. Investigations in yeast and
in human cells have revealed that MSH6 is essential
for MMR and is involved in repair of single-nucleotide
mismatches (Drummond et al. 1995; Palombo et al.
1995). Interestingly, tumors in MSH6 knockout mice
display an MSI-low phenotype (Edelmann et al. 1997).
To test a possible involvement ofMSH6 in patients with
MSI-low tumors, we used two-dimensional DNA elec-
trophoresis to scan MSH6 (for cDNA sequence, see
GenBank accession number U28946; for exon and in-
tron boundaries, see GenBank accession numbers
U73732–U73737), as well as MSH2 and MLH1, for
germline mutations in three unrelated patients who had
MSI-low tumors and were from families fulfilling the
Amsterdam criteria and in 36 patients with suspected
HNPCC, who were divided, according to the results of
MSI testing, into an MSI-low group ( ) and ann = 18
MSI-high group ( ) (see the Patients and Methodsn = 18
section, below).
Patients and Methods
Patients
Patients were included in the study if they fulfilled
at least one of the following criteria: (1) diagnosis of
CRC or endometrial cancer at age !50 years; (2) di-
agnosis of any HNPCC-associated tumor (gastric,
small bowel, ovarian, urothelial, pancreatic, or bile
duct) and a first-degree relative with a diagnosis of
CRC or endometrial cancer, or vice versa, with one
of the individuals receiving such a diagnosis at age
!50 years; and (3) diagnosis of more than one
HNPCC-associated cancer, irrespective of patient age.
These were the inclusion criteria for our prospective
population-based study of the occurrence of germline
MMR gene mutations in individuals with suspected
HNPCC. The patients in the present study represent
the first 21 patients consecutively included in that
study plus 15 consecutive patients who were seen at
the Department of Medical Genetics, University of
Groningen, Groningen, The Netherlands, for sus-
pected HNPCC but who did not fulfill the original
Amsterdam criteria for HNPCC. In addition, three
patients who had MSI-low tumors and were from
families meeting the Amsterdam criteria were
included.
MSI
MSI criteria and primers that were used were recently
defined at an international workshop on HNPCC in Be-
thesda (Boland et al. 1998). They include two mono-
nucleotide repeats (BAT25 and BAT26) and three di-
nucleotide repeats (D2S123, D5S346, and D17S250).
DNA was extracted from formalin-fixed paraffin-em-
bedded sections of dissected tumor tissues, as described
elsewhere (Goelz et al. 1985), and from peripheral-blood
lymphocytes. PCR products were analyzed, on 6% de-
naturing polyacrylamide gels, with the use of an A.L.F.
DNA sequencer (Pharmacia LKB.). For data analysis, a
DNA-fragment analyzer (Pharmacia) was used. Tumors
were classified as MSI-high when two or more of the
five markers showed instability or as MSI-low when
none of the markers—or only one marker—showed
instability.
To distinguish microsatellite-stable (MSS) from
MSI-low tumors in patients with germline MSH6 mu-
tations, 10 additional markers were evaluated (Ed-
wards et al. 1992; Chen et al. 1995; Parsons et al.
1995; Dietmaier et al. 1997; Boland et al. 1998).
These included three mononucleotide repeats (BAT40,
52H10, and BAT17), five dinucleotide repeats
(D1S158, D10S197, D13S153, D18S58, and
D18S69), one trinucleotide repeat (FABP2), and one
tetranucleotide repeat (D15S1232). BAT17 is a
poly(A)17 tract localized in the acceptor-splice site of
exon 10 of the MSH6 gene. PCR amplification of
BAT17 was performed with the use of primers 5′-
GGAAGGGATGATGCACTATG-3′ and 5′-GTTTAT-
TAGATCATAATGTT-3′.
Using these 10 additional markers, we classified tu-
mors either as MSI-high, when 5 (33%) of the 15
markers showed MSI, or as MSI-low, when !5 markers
showed MSI. MSS tumors were characterized by the
absence of instability in all 15 microsatellite loci tested.
Mutation Analysis
Mutation analysis of MSH2, MLH1, and MSH6 was
performed by means of two-dimensional DNA electro-
phoresis (Wu et al. 1996). For MSH2 and MLH1, the
analysis was performed as described elsewhere (Wu et
al. 1997). The primers used for amplification of all 10
exons of theMSH6 gene are listed in table 1, along with
the fragment sizes, melting temperatures, PCR annealing
temperatures, and multiplex PCR groups that were used.
Exon 1 was divided into two amplicons, which were
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Table 1
Oligonucleotides Used for Amplification and Two-Dimensional DNA Analysis of the MSH6 Gene
Exon
Primers
(5′r3′)
Size
(bp)
Melting
Temperature
(˚C)
Annealing
Temperature
(˚C) Multiplex PCR
1a [40GC] TCCGTCCGACAGAACGGTTG
TTCGCGTGAGGCCCTGGCCGA
208 79 58
1b CGCTGAGTGATGCCAACAAG
[55GC] CAACCCCCTGTGCGAGCCTC
355 84 58
2 AACTAAGTTATGTATTTCCT
[40GC] CCTGTCTGTCTGTTTCTCTC
334 72 50 d
3a [40GC] GAACTGCTGGGATTACAGTC
GTATTTCAGGCTTTGCACTG
170 66 52 a
3b [40GC] ttttttttttCCCAGAAGGGAGGTCATTTT
cgcccCCCCATCACCCTAACATAAA
255 72 52 d
4a [40GC] CCAAATTTTGATTTGTTTTT
CCACATCAGAGCCACCAATG
247 69 50 f
4b cgcccCGAAGGGTCATATCAGATTC
[40GC] ttttttttttATACCAAACAGTAGGGCGAC
412 72 55 b
4c CGTTAGTGGAGGTGGTGATG
[40GC] tttttttttt ATGAATACCAGCCCCAGTTC
353 70 55 c
4d CTGTACCACATGGATGCTCT
[40GC] CTTCCTCTTTTTCTTTGAGG
381 71 52 e
4e CCTCTGAGAACTACAGTAAG
[40GC] CCAAAACTGGGAGCCGGGTA
333 68 52 c
4f CTGTTCTCTTCAGGAAGGTC
[40GC] AGCCATTGATAAAAGCTCCT
311 70 52 f
4g [40GC] CCTCAAAAAATGCCTTATTG
AGCCATTGCTTTAGGAGCCG
304 69 52 g
4h ACTTGCCATACTCCTTTTGG
[40GC] TCCAGAGCAGAAAGAAAATC
339 70 50 b
4i [40GC] CTACATACAGCAAGAAGAAG
CCTGCTTTGGGAGTAATAAG
293 68 52 e
4j [40GC] GAAAAGGCTCGAAAGACTGG
TCGTTTACAGCCCTTCTTGG
301 71 52 a
4k [40GC] GAAGAATACGAGTTGAAATC
GCACTACTTATCAAAGCCTG
284 70 52 d
5a [40GC] AAAACCCCCAAACGATGAAG
GTCTTCGTAATGCAAGGATG
220 72 52 c
5b [40GC] ttttttttttCTTAGAGCTTAAAGGATCAC
cgcccCTTTCTGATAACAAAACTTT
263 69 52 g
6 cgcccGTTTATGAAACTGTTACTACC
[40GC] GCAAATATCTTTTATCACAT
282 70 52 a
7 [40GC] GAGTATTCATTTGTGATTTT
CGCCCATGTTTTTAAGATAGTCTTC
211 66 50 g
8 [40GC] CCTTTTTTGTTTTAATTCCT
CAACAGAAGTGCCCTCTCAA
308 67 52 b
9 TTTTGAGAGGGCACTTCTGT
[40GC] CCCCTTTTACTGTTTCTTTG
365 68 52 f
10 ATTTTAAGGGAAGTTTGCC
[40GC] GTTTATTAGATCATAATGTT
206 68 50 e
10sa GGAAGGGATGATGCACTATG
GTTTATTAGATCATAATGTT
218 52
a The acceptor-splice site of exon 10 of hMSH6 is analyzed by direct sequencing.
amplified separately because of their exceptionally high
GC content. Primers were designed to jointly encompass
all exons plus intron-exon boundaries, with the excep-
tion of the acceptor-splice site of exon 10, where the
nature of the flanking intronic sequences did not allow
the design of primers for denaturing gradient gel elec-
trophoresis (DGGE). This splice site was analyzed by
means of direct sequencing.
Multiplex PCR was performed on 400 ng DNA in a
total volume of 50 ml. The PCR mixture contained
reaction buffer, 1 mM MgCl2, 0.5 U Taq DNA1# Taq
polymerase (HT Biotechnology), 0.75 mM each dNTP,
and 10 pmol each primer. A step-down PCR program
was used for multiplex PCR. The PCR profile consisted
of denaturation at 94C for 3 min; then 5 cycles each
for 1 min at 94C, 1 min at 56C, and 2 min at 72C;
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Table 2
MSI of Tumors from Patients with Germline MSH6 Mutations
STATUS OF MICROSATELLITE LOCUSb
PATIENT (TUMOR)a BAT25 BAT26 BAT40 BAT17 52H10 D1S158 D2S123 D5S346 D10S197 D13S153 D17S250 D18S58 D18S69 FABP2 D15S1232
D840 (EC)               
D716c (CRC)               
HNPCC49 (EC)               
HNPCC49 (CRC)               
D805 (CRC)      -         
Div448 (EC)          ND     
Div682 (CRC)               
a CRC = colorectal carcinoma; EC = endometrial carcinoma.
b A minus sign () denotes that the individual is MSI negative; a plus sign (), MSI positive; a plus/minus sign (), possible MSI positive; ND, not determined.
c Patient from family meeting the Amsterdam criteria.
then 5 cycles each for 1 min at 94C, 1 min at 53C,
and 2 min at 72C; and then 25 cycles each for 1 min
at 94C, 1 min at 50C, and 2 min at 72C. Elongation
was for 5 min at 72C. The exon 1 fragments were
amplified separately in a 50-ml reaction mixture con-
taining 100 ng genomic DNA, 0.25 mM each dNTP, 10
pmol each primer, and 0.125 U Taq DNA polymerase.
To increase the amount of heteroduplex molecules, a
heteroduplex step was performed after PCR amplifica-
tion—that is, the samples underwent a denaturation step
for 10 min at 96C, followed by renaturation for 1 h at
50C.
For mutation analysis of MSH6, PCR products were
mixed in equal amounts, were ethanol precipitated, and
then were redissolved. A 30-ml mixture of the amplified
exons was first subjected to size separation in a 0.75-
mm-thick 9% polyacrylamide (PAA) gel (acrylamide:
bisacrylamide 37.5:1) in (1 # TAE = 400.5# TAE
mM Tris, HAC pH 8.0, 20 mM NaAc, 1 mM
Na2EDTA) at 200 V/19 cm and 50C for 5 h. The
separation pattern was visualized with the use of eth-
idium bromide (EtBr) staining for 10 min and with UV
transillumination of the gel, which was lying on a glass
plate to protect the DNA fragments from damage
caused by UV light. The 100–600-bp region in the mid-
dle part of the lane was cut out and was applied to a
1-mm-thick 9% PAA gel containing a denaturing gra-
dient of 30%–60% urea-formamide (UF) (100% UF
contains 7 M urea and 40% deionized formamide) and
a 0%–7% glycerol gradient. Two-dimensional DNA
electrophoresis was performed, at 110 V/19 cm, for 17
h at 56C. After the DNA was stained with EtBr, the
gel pattern was documented.
Fragments of exon 1 were applied to a 0.75-mm-thick
9% PAA gel containing a combined denaturing gel (Wu
et al. 1999). This gel consisted of a constant denaturant
gel electrophoresis part in the lower 10 cm of the gel
(78% UF denaturant) and a DGGE part in the upper 9
cm of the gel (30%–78% UF). The DNA was run at
150 V/19 cm for 10 h at 60C.
Sequencing of Amplified Fragments
Variants were confirmed by direct sequencing of in-
dependently amplified PCR products, in both sense and
antisense directions, by use of the same primers thatwere
used for DGGE (without the GC-clamp). Sequencing
was performed with an ABI PRISM 377 DNA sequencer
(PE Biosystems).
Results
MSI
Two tumors from the three unrelated patients with
HNPCC did not display any instability at the five tested
loci. The tumor from the third patient exhibited insta-
bility at one locus (D5S346). Of the 36 patients with
suspected HNPCC, 15 had tumors that did not display
any instability at the five tested loci. Tumors from three
patients exhibited instability at one locus (BAT25,
D2S123, and D5S346). Tumors from the other 18 pa-
tients with suspected HNPCC displayed an MSI-high
phenotype; tumors from 13 of these patients showed
MSI in more than three tested markers.
To distinguish MSS from MSI-low tumors in the
five patients (families) with germlineMSH6mutations
and MSI-low/MSS tumors, 10 additional markers
were used for the MSI analysis (table 2). Neither pa-
tient HNPCC49-1 nor patient HNPCC49-2, two pa-
tients from the same family with suspected HNPCC,
displayed any instability at the 15 tested markers. Tu-
mors from the index patients of families Div682 and
D805 displayed instability at a single locus (BAT40
and D2S123, respectively), whereas tumor DNA from
patient D840 displayed instability at four loci
(BAT17, D2S123, D18S58, and D18S69). Tumor
DNA from patient D716, who had HNPCC, displayed
instability at a single locus (D18S58). Tumor DNA
from index patient Div 448, who had an MSI-high
phenotype, was also tested for the additional 10 mark-
ers. Instability was detected at 6 (BAT 40, BAT17,
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Table 3
Germline Mutations of the MSH6 Gene
MUTATION ANALYSIS
PATIENT EXON/INTRON LOCATION Nucleotide Change
Predicted Protein
Change MSI STATUS
D840 Exon 2 Codon 144 AGCrATC SerrIle Low
D716a Exon 4a Codon 217 InsT (GATrGATT) Early stop codon Low
HNPCC 49 Exon 4a Codon 217 InsT (GATrGATT) Early stop codon Low
D805 Exon 4a Codon 217 InsT (GATrGATT) Early stop codon Low
Div448 Exon 4h Codon 850 TACrTGC TyrrCys High
Div682 Exon 8 Codon 1258 CAArTAA GlnrStop codon Low
D854 Intron 10 40 of exon 9 trc 43 of exon 9 insertion 10 base (ctgaccttaa) ? Low
a Patient from family meeting the Amsterdam criteria.
D2S123, D5S346, D17S250, and D18S58) of the 15
loci tested. Addition of the 10 extra microsatellite
markers did not change the MSI status of any of the
patients analyzed.
Mutation Analysis
In one of the three index patients from the Amsterdam
families, a frameshift mutation (217insT) was detected
in exon 4 (table 3). Since this mutation results in a pre-
mature stop codon leading to a protein that is 1,143
amino acids shorter than the wild-type gene product, we
consider it to be pathogenic. Nomutations were detected
in the remaining two index patients.
In the 18 patients with suspected HNPCC and MSI-
low tumors, four presumably pathogenic germline
MSH6 mutations were detected (table 3). In two of the
index patients, the mutation was the same frameshift
mutation (217insT) detected in the patient from the Am-
sterdam family. In both patients, the mutation appeared
to be homozygously present when the fragment with a
forward primer located 62 bp upstream from the intron-
exon boundary of exon 4 was analyzed. However, when
a forward primer that was 54 bp upstream from the
intron-exon boundary was chosen, the frameshift mu-
tation was present in a heterozygous state. The apparent
homozygous state of the mutations in the first analysis
is due to an intronic mutation that is located in the first
forward primer–recognition site and that results in am-
plification of only the mutant allele. In the pedigree of
one of the patients, the same frameshift mutation was
also present in another individual with colon cancer (fig.
1). The presence of the 217insT mutation in two un-
related patients with suspected HNPCC and in one pa-
tient with HNPCCmight indicate a founder origin.Hap-
lotype analysis was performed with the use of four
intragenic informative single-nucleotide polymorphisms
(SNPs) located in exons 2–4 and 7 of the MSH6 gene.
A common haplotype was found in all three patients,
making a founder effect likely (data not shown). In the
third index patient, a Gln1258 stop mutation was found
in exon 8 (fig. 2B). This results in a presumably path-
ogenic truncated protein that is 102 amino acids shorter
than the wild-type gene product. In the fourth index
patient, a missense mutation (Ser144Ile) was detected in
exon 2. This mutation might be considered pathogenic,
since it results in a substitution of amino acids belonging
to different polarity groups and since it is located in a
conserved codon (Corradi et al. 1996). Furthermore, this
mutation was not present in 200 control individuals. The
four mutations account for 22% of the unrelated pa-
tients with MSI-low tumors who were investigated. In
addition to these mutations, an insertion of 10 nucleo-
tides (ctgaccttaa) was found at 43 of exon 9. Again,
this variant was not present in 200 control samples. A
pathogenic nature of this variant can be neither con-
firmed nor excluded. Neither MSH2 nor MLH1 muta-
tions were identified in any of the 18 patients who were
MSI-low. In the 18 patients who were MSI-high, one
MSH6 missense mutation, Tyr850Cys in exon 4, was
detected. This mutation might be considered pathogenic,
since it results in a substitution of amino acids belonging
to different polarity groups and since it was not present
in 200 control samples. In addition to this MSH6 mu-
tation, however, an MLH1 frameshift mutation
(649delC) was detected in the same patient. Pedigrees
of the five families who had suspected HNPCC and
MSH6 mutations are shown in figure 1.
Discussion
To date (July 1999), 229 different germline muta-
tions in five MMR genes (MSH2, MLH1, PMS1,
PMS2, andMSH6) have been reported to the database
of the International Collaborative Group on HNPCC
(ICG-HNPCC). Among these mutations are two caus-
ative MSH6 mutations. To verify our hypothesis that
the MSI-low phenotype in patients with HNPCC or
suspected HNPCC might be associated with germline
MSH6 mutations, we used two-dimensional DNA
electrophoresis to scan MSH6 for germline mutations
both in patients with HNPCC who had MSI-low tu-
mors and in patients with suspected HNPCC who had
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Figure 1 Pedigrees of the five families with suspected HNPCC and MSH6 mutations. Of these five families, four (D805, D840, Div682,
and HNPCC49) had MSI-low tumors. The index patient in family Div448 had a tumor displaying an MSI-high phenotype. Squares represent
males; circles, females; diagonal stripes, patients who died; unblackened symbols, no tumor; blackened symbols, patients with histologically
verified carcinomas; gray symbols, patients with tumors that were not histologically verified. Abbreviations indicate the site of cancer: bas =
basocellular; bili = bile duct; brc = breast; cns = brain; cra = adenoma of the colon; crc = colon; end = endometrium; leu = leucemia; lu = lung;
ov = ovary; pr = prostate; pyl = pyelum; sk = skin; st =stomach; ure = ureter; ? = tumor of unknown origin. The numbers after the abbreviations
indicate the age at onset of cancer diagnosis.
either MSI-low or MSI-high tumors. Indeed, four pre-
sumably causative germlineMSH6mutations were de-
tected in the MSI-low group of patients who fulfilled
one or more of our criteria (table 3) (see the Patients
and Methods section, above). They account for 22%
of our patients who have suspected HNPCC and MSI-
low tumors. An additional germline MSH6 mutation
was detected in one of the three index patients from
families who met the Amsterdam criteria and had
MSI-low tumors (table 3), and one MSH6 missense
mutation was found in a patient with an MSI-high
endometrial tumor. This patient, however, also had an
MLH1 mutation, which may explain the MSI-high
phenotype. Our results suggest that MSH6 may be
involved in a substantial proportion of patients with
HNPCC or suspected HNPCC and MSI-low tumors.
It has been suggested that tumors from patients with
an MSH6 germline mutation would preferably have in-
stability of A-track markers (Papadopoulos et al. 1995;
Akiyama et al. 1997; Miyaki et al. 1997). We found that
in three of the six index patients with germline MSH6
mutations, tumors exhibited instability at one or two A-
track markers (BAT40 and BAT17). Our results, how-
ever, do not confirm the A-track instability hypothesis.
Furthermore, no significant correlation could be detected
between instability of specific MSI markers and the pres-
ence of an MSH6 mutation (table 2).
We also did not find a difference in instability of the
different types of markers (mono-, di-, tri-, or tetranu-
cleotide repeat markers) in different tumor types (table
2). Of course, one should keep in mind that these tumors
are all MSI-low or MSS.
The two other MSH6 germline mutations reported to
date (Akiyama et al. 1997; Miyaki et al. 1997) were
detected in families with MSI-high tumors. That most
attention has been paid to families who have HNPCC
tumors displaying an MSI-high phenotype might be an
explanation for the low frequency of reported MSH6
mutations. Another explanation might be compound
heterozygosity with an MLH1 or MSH2 mutation, as
was found in one of our patients. A third explanation
might be an altered tumor phenotype. As in most tu-
mors, some instability is observed, and it very well might
be that, with progression of the tumor, the genomic in-
stability increases and, consequently, tumors might
change from an MSI-low to an MSI-high phenotype.
Recently, the ICG-HNPCC has modified the Amster-
dam criteria by substituting HNPCC-associated cancers
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Figure 2 Two-dimensional DNA separation patterns of the 21 PCR-amplified fragments representing all exons of the MSH6 gene, with
the exception of exon 1. Exon 4 is amplified in 11 fragments; exons 3 and 5 are each amplified in two fragments. A, Two-dimensional separation
pattern of a control individual. B, Two-dimensional separation pattern from patient Div682 (see table 1). Comparison of A and B clearly shows
a heterozygous mutation in exon 8 of patient Div682. This mutation results in four spots (two homoduplexes and two heteroduplexes).
(colorectal cancer or cancer of the endometrium, small
bowel, ureter, or renal pelvis) for colorectal cancer. The
revised ICG-HNPCC criteria are called “Amsterdam cri-
teria II” (Vasen et al. 1999). Six of our 36 families with
suspected HNPCC fulfilled these revised criteria. Pa-
tients from two of these families had MSH6 mutations
(fig. 1). We also looked for correlations between the
pattern of HNPCC-associated tumors in the families and
the presence (fig. 1) or absence of an MSH6 mutation.
Although we did not find any correlation, we noticed
that the three index patients from the families who had
suspected HNPCC and an MSH6 mutation had been
given a diagnosis at !50 years of age and that endo-
metrial tumors were observed in two of the three fam-
ilies. These observations may be the result of the selec-
tion criteria used. Also, brain tumors appeared to occur
in two of the three families (fig. 1).
Our results may have important consequences for the
genetic testing and management of families who have
HNPCC and suspected HNPCC and MSI-low tumors.
Additional confirmatory studies, however, are required
to establish the full significance of our findings.
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